Anna Maria Paoletti

Anna Maria Paoletti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Maria Paoletti has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Gian Benedetto Melis

    Dipartimento Chirurgico Materno Infantile e di Scienza delle Immagini, Sezione di Clinica Ginecologica, Ostetrica e Fisiopatologia della Riproduzione Umana, Universita' degli Studi di Cagliari, Italy

    10 shared publications
  • Gian Benedetto Melis

    University of Cagliari. Operating Unit of Gynecology and Obstetrics of the University Hospital of Cagliari (AOU CA), “Duilio Casula” University Hospital, Monserrato (CA)

    8 shared publications
  • Manuela Neri

    Department of Obstetrics and Gynecology and Gynecological Oncology, Azienda di Rilievo Nazionale ed Alta Specializzazione “G. Brotzu”, Piazza A. Ricchi 1, 09121 Cagliari, Italy

    7 shared publications
  • Bruno Piras

    University of Cagliari. Operating Unit of Gynecology and Obstetrics of the University Hospital of Cagliari (AOU CA), “Duilio Casula” University Hospital, Monserrato (CA)

    5 shared publications
  • Monica Pilloni

    University of Cagliari. Operating Unit of Gynecology and Obstetrics of the University Hospital of Cagliari (AOU CA), “Duilio Casula” University Hospital, Monserrato (CA)

    5 shared publications
  • Pierina Zedda

    University of Cagliari. Operating Unit of Gynecology and Obstetrics of the University Hospital of Cagliari (AOU CA), “Duilio Casula” University Hospital, Monserrato (CA)

    5 shared publications

Latest Publications

  • Open Access

    Family Planning

    by Anna Maria Paoletti, Gian Benedetto Melis, Bruno Piras, Monica Pilloni, Pierina Zedda, Maria Francesca Marotto, Valerio Vallerino, Anna Melis, Valeria Taccori, Virginia Melis, et al.

    The contraception (the term is the fusion between “contra”, against, and conception): includes all methods that prevent conception. According to the physiology of human reproduction, the contraceptive methods can prevent the fecundation by hindering the female and male gametes meeting. In these mechanisms we include: The abstinence by sexual intercourse around the ovulatory phase of the cycle; The use of barriers that block contact between male gametes and female genitalia; The use of methods impeding the ascent of spermatozoa through the female genital tracts (intrauterine devices). The prevention of the oocyte from being available (hormonal contraceptives or oral contraceptives, OC). In this category there is the availability of short acting reversible contraception (SARC) (pill, vaginal ring, patch), and the long acting reversible contraception (LARC) (progestin implants). The ideal contraceptive method has to respond to four fundamental principles: efficacy, safety, reversibility, tolerability. The authors will discuss all the above contraceptive methods with the evaluation of indications and contraindications to each method.


  • Open Access

    Oxidative Stress: The Role of Estrogen and Progesterone

    by Angelo Cagnacci, Irene Gazzo, Sara Stigliani, Anna Maria Paoletti, Paola Anserini, Ambrogio Pietro Londero, Anjeza Xholli

    The effect of estrogen and progesterone on oxidative status is not yet very clear, improvements and detrimental effects having been reported with the use of menopausal hormone therapy or hormonal contraceptives, respectively. In this study, we evaluated the role played by estrogen and progesterone separately, on the oxidative status of 32 women, 18 to 43 years old, by inducing high levels of estrogen and then adding high levels of progesterone. During a cycle of in vitro fertilization, blood samples were collected prior to gonadotrophin stimulation (low estradiol levels), on the day of oocyte retrieval (high levels of estrogen), and on the day of embryo transfer (high levels of estrogen and progesterone). Total blood levels of oxidants (FORT), antioxidants (FORD), and their ratio FORT/FORD were measured using a colorimetric method based on the Fenton reaction. Seven women measured their early morning body temperature at the same time points. FORT significantly decreased from the low- to the high-estrogen phase (p = 0.023) and increased from the high-estrogen to the high-estrogen–progesterone phase (p = 0.006). FORD showed an opposite but non-significant trend. The FORT/FORD ratio decreased from the low- to the high-estrogen phase (p = 0.0104) and increased from the high-estrogen to the high-estrogen –progesterone phase (p = 0.004). Body temperature (n = 7) decreased in the high-estrogen phase (p = 0.001) and increased from the high-estrogen to the high-estrogen–progesterone phase (p = 0.001). In the seven women, FORT (p = 0.009) and FORT/FORD (p = 0.0056) were linearly related to body temperature values. Our data show opposite effects of estrogen and progesterone on oxidative status. These effects seem to be related to the effect exerted on body temperature regulation.


  • Mental health in women undergoing gynecological surgery at risk of infertility

    by Gioia Mura, Cristina Sechi, Laura Vismara, Valentina Moi, Manuela Neri, Anna Maria Paoletti

    Surgery for benign gynecologic conditions may lead to infertility complications. In a cross-sectional study we investigated depressive and anxiety symptoms, Quality of Life (QoL), and coping strategies in women with benign gynecologic conditions undergoing surgical treatment (G1, N = 45) compared with women that did not need surgery (G2, N = 43), through the Patient’s Health Questionnaire, the Short Form Health Survey-12 items, the Self-Rating Anxiety State, and the Brief COPE. Statistical analyses showed that women in G1 had significant higher depressive (p=.04) and anxiety (p=.03) symptoms, and lower QoL (p=.01), than did those in G2. Moreover, women with more depressive or anxiety symptoms in both groups were more likely to present maladaptive coping modalities. A careful evaluation of the mental health of women undergoing gynecological surgery at risk of infertility should be included in the care for benign gynecologic conditions, in order to prevent psychosocial distress and alleviate the burden on QoL.


  • Contraception in Perimenopausal Women

    by Manuela Neri, Anna Maria Paoletti, Valerio Vallerino, Bruno Piras, Elena Giancane, Monica Pilloni, Anna Melis, Valeria Taccori, Pierina Zedda, Gian Benedetto Melis

  • Open Access

    Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued?

    by A. Cagnacci, G. Bonaccorsi, M. Gambacciani, V. De Leo, C. Di Carlo, G. Bifulco, S. Alfieri, N. Biglia, S. Caruso, E. Cicinelli, et al.


  • Systemic therapy for the treatment of endometrial cancer

    by Manuela Neri, Michele Peiretti, Gian Benedetto Melis, Bruno Piras, Valerio Vallerino, Anna Maria Paoletti, Clelia Madeddu, Mario Scartozzi, Valerio Mais

    Introduction: Endometrial cancer (EC) is one of the most frequent gynecological cancers worldwide. The gold standard treatment of EC is most certainly surgery and may very well be the only therapy in the early stages of disease. To improve outcomes in non-early EC, adjuvant therapy is often employed but this is not standardized. Adjuvant options can include radiotherapy, chemotherapy or a combination of both. Adjuvant chemotherapy could be indicated in high-risk stage I and II or advanced stage EC. Several clinical trials are ongoing in an attempt to define the optimal adjuvant treatment. Furthermore, chemotherapy is the front-line therapy in advanced unresectable, metastatic or recurrent endometrial cancer. Areas covered: Herein, the authors review the first-line chemotherapy for the treatment of endometrial cancer and provide their expert perspectives on these therapies. Expert opinion: Chemotherapy is fundamental in advanced/recurrent EC. Further evidence is needed to characterize the role of adjuvant chemotherapy. Future studies should consider genomic and molecular heterogeneities to identify even more efficient tailored therapies.


  • Uterine Myoma

    by Stefano Guerriero, Silvia Ajossa, Alba Piras, Eleonora Musa, Virginia Zanda, Valerio Mais, Anna Maria Paoletti

    Uterine fibroids (also known as leiomyomas or myomas) are the most common type of benign uterine tumors that originate from the myometrium, and are made of extracellular matrix with collagen, fibronectin, and proteoglycans. 1

  • Repeated two cycles of ulipristal acetate treatment improve the quality of life in premenopausal women with heavy menstrual bleeding dependent on uterine myomas, without impairment of bone health

    by Manuela Neri, Monica Pilloni, Anna Maria Paoletti, Gian Benedetto Melis, Bruno Piras, Silvia Ajossa, Maria Francesca Marotto, Valentina Corda, Alessandro Ronchi, Elena Giancane, et al.

    This observational study was conducted in premenopausal women who presented themselves at the Obstetrics and Gynecology Department of the University Hospital of Cagliari (Italy), for heavy menstrual bleeding (HMB) dependent on uterine myomas. After a screening visit, 19 women without contraindications to ulipristal acetate (UPA) treatment, were included in the study that envisaged 12 months of observation in which each subject was asked to assume UPA (tablet of 5 mg, ESMYA®, one tablet a day for 3 months: first cycle) two menstrual cycles of interruption and a second ESMYA® cycle, followed by 3 months of observation (third follow-up month, visit 4). The significant decrease of myoma volume, diagnosed after the first ESMYA® cycle, persisted until the visit 4. The HMB significantly decreased during the ESMYA® treatment and persisted until visit 4. The quality of life (QoL), evaluated with the questionnaire SF-36, significantly improved during the study. The values of estradiol (E2), biochemical parameters of bone metabolism, as well as those of lumbar and hip bone mineral density, did not change during the study in comparison with basal levels. The efficacy of two repeated ESMYA® cycles to treat uterine myomas and their related symptoms improves the QoL without interfering with bone health.


  • Vilaprisan for treating uterine fibroids

    by Gian Benedetto Melis, Manuela Neri, Bruno Piras, Anna Maria Paoletti, Silvia Ajossa, Monica Pilloni, Maria Francesca Marotto, Valentina Corda, Alessandra Saba, Elena Giancane, et al.

    Introduction: The medical strategy to antagonize myoma size and related-symptoms is to reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH agonist (GnRHa) or with compounds that antagonize progesterone stimulatory activity on myomas. Selective progesterone receptor modulators (SPRMs) bind progesterone receptor (PR), leading to both agonist and antagonist effects. The result of SPRMs’s action is tissue-specific and it depends on the particular affinity and strength of each SPRM. Area covered: Ulipristal acetate (UPA) is the first SPRM registered for myoma treatment. UPA reduces heavy uterine bleeding within 7 days from the onset of treatment, whereas a longer time is required with GnRHa treatment. Vilaprisan is a novel powerful SPRM. Phase I and II studies give encouraging results on the efficacy of vilaprisan at different doses. Like other SPRMs, vilaprisan induces benign changes of endometrium (PR modulator-associated endometrial changes, PAECs). These disappear as treatment is discontinued. Unlike GnRHa treatment, neither UPA nor vilaprisan induce hypoestrogenism and associated symptoms. Phase III studies are ongoing to confirm efficacy and safety of vilaprisan in long-term treatment of symptomatic fibroids. Expert opinion: It is fundamental to underline the rapidity of action (only 3 days) in the control of myoma-related bleeding.


  • The stimulation of the vaginal immune system with short-term administration of a vaginal gel containing fraction of Propionibacterium acnes, hyaluronic acid and polycarbophil is efficacious in vaginal infections dependent on disorders in the vaginal ecosystem

    by Gian Benedetto Melis, Bruno Piras, Maria Francesca Marotto, Manuela Neri, Valentina Corda, Valerio Vallerino, Alessandra Saba, Stefano Lello, Monica Pilloni, Pierina Zedda, et al.

    The vaginal immune system (VIS) is the first defense against antigens recognized as foreign. Substances capable of locally activating the VIS could be a valid strategy to treat vulvo-vaginal infections (VVI), caused by changes in the vaginal ecosystem, such as bacterial vaginosis (BV), vulvo-vaginal candidiasis (CA), and mixed vaginitis (MV). Bacterial lysates, obtained by crushing bacterial cultures, exert immuno-modulatory activities. The parietal fraction from Propionibacterium acnes is a patent of Depofarma (MoglianoVeneto, Italy). The preparation that associates such fraction to hyaluronic acid and polycarbophil is a registered trademark, commercially available in Italy as vaginal gel, Immunovag®. The study aimed to evaluate whether a 5-day-treatment with Immunovag® improves the symptoms and signs of VVI, in 60 women with Gardnerella vaginalis (GV), 154 with CA, 95 with MV, diagnosed with vulvar vaginal swab (VVS), and in 283 with BV, diagnosed with the Amsel criteria. At the end of the treatment (visit 2), the symptoms and signs of VVI disappeared in a significant number of subjects (χ2p < .02 vs pre-treatment) in all VVI groups, and their intensity was significantly (p < .0002) reduced in the subjects in which they were still present. Immunovag® represents a valid treatment of VVI induced by changes in the vaginal ecosystem.